AKR1C2 and esophageal squamous cell carcinoma: Our study demonstrated that UDCA, a selective inhibitor of AKR1C2 enzyme activity,38 could attenuate the proliferation and migration of ESCC cells and that the combined use of cisplatin with UDCA could increase antitumour effect as compared with single drug.